815 related articles for article (PubMed ID: 31365790)
1. The influence of microenvironment on tumor immunotherapy.
Zhang J; Shi Z; Xu X; Yu Z; Mi J
FEBS J; 2019 Nov; 286(21):4160-4175. PubMed ID: 31365790
[TBL] [Abstract][Full Text] [Related]
2. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers for Checkpoint Inhibition.
Weber JS
Am Soc Clin Oncol Educ Book; 2017; 37():205-209. PubMed ID: 28561695
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for Immunotherapy: Current Developments and Challenges.
Spencer KR; Wang J; Silk AW; Ganesan S; Kaufman HL; Mehnert JM
Am Soc Clin Oncol Educ Book; 2016; 35():e493-503. PubMed ID: 27249758
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment.
Omar HA; El-Serafi AT; Hersi F; Arafa EA; Zaher DM; Madkour M; Arab HH; Tolba MF
FEBS J; 2019 Sep; 286(18):3540-3557. PubMed ID: 31306553
[TBL] [Abstract][Full Text] [Related]
6. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
7. Targeting galectins in T cell-based immunotherapy within tumor microenvironment.
Jin QY; Li YS; Qiao XH; Yang JW; Guo XL
Life Sci; 2021 Jul; 277():119426. PubMed ID: 33785342
[TBL] [Abstract][Full Text] [Related]
8. Regulatory Mechanisms of Inhibitory Immune Checkpoint Receptors Expression.
Curdy N; Lanvin O; Laurent C; Fournié JJ; Franchini DM
Trends Cell Biol; 2019 Oct; 29(10):777-790. PubMed ID: 31378317
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial Cancer Immunotherapies.
Hellmann MD; Friedman CF; Wolchok JD
Adv Immunol; 2016; 130():251-77. PubMed ID: 26923003
[TBL] [Abstract][Full Text] [Related]
10. Tissue Site and the Cancer Immunity Cycle.
Horton BL; Fessenden TB; Spranger S
Trends Cancer; 2019 Oct; 5(10):593-603. PubMed ID: 31706507
[TBL] [Abstract][Full Text] [Related]
11. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
[TBL] [Abstract][Full Text] [Related]
12. Role of cell surface proteoglycans in cancer immunotherapy.
Espinoza-Sánchez NA; Götte M
Semin Cancer Biol; 2020 May; 62():48-67. PubMed ID: 31336150
[TBL] [Abstract][Full Text] [Related]
13. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy.
Rivadeneira DB; Delgoffe GM
Clin Cancer Res; 2018 Jun; 24(11):2473-2481. PubMed ID: 29386217
[TBL] [Abstract][Full Text] [Related]
14. Targeting innate sensing in the tumor microenvironment to improve immunotherapy.
Liu Z; Han C; Fu YX
Cell Mol Immunol; 2020 Jan; 17(1):13-26. PubMed ID: 31844141
[TBL] [Abstract][Full Text] [Related]
15. Current status of immunotherapy.
Suzuki S; Ishida T; Yoshikawa K; Ueda R
Jpn J Clin Oncol; 2016 Mar; 46(3):191-203. PubMed ID: 26819277
[TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets.
Tsai HF; Hsu PN
J Biomed Sci; 2017 May; 24(1):35. PubMed ID: 28545567
[TBL] [Abstract][Full Text] [Related]
17. PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy.
Conciatori F; Bazzichetto C; Falcone I; Ciuffreda L; Ferretti G; Vari S; Ferraresi V; Cognetti F; Milella M
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32727102
[TBL] [Abstract][Full Text] [Related]
18. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy.
Phuengkham H; Ren L; Shin IW; Lim YT
Adv Mater; 2019 Aug; 31(34):e1803322. PubMed ID: 30773696
[TBL] [Abstract][Full Text] [Related]
19. Tumor inherent interferons: Impact on immune reactivity and immunotherapy.
Brockwell NK; Parker BS
Cytokine; 2019 Jun; 118():42-47. PubMed ID: 29681426
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk between T lymphocyte and extracellular matrix in tumor microenvironment.
Lv D; Fei Y; Chen H; Wang J; Han W; Cui B; Feng Y; Zhang P; Chen J
Front Immunol; 2024; 15():1340702. PubMed ID: 38690275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]